Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

Published:2017-12 Issue:12 Volume:23 Page:2065-2069
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Bhamidipati Pavan Kumar^ORCID,Fiala Mark A.,Grossman Brenda J.,DiPersio John F.,Stockerl-Goldstein Keith,Gao Feng,Uy Geoffrey L.,Westervelt Peter,Schroeder Mark A.,Cashen Amanda F.,Abboud Camille N.,Vij Ravi

Funder

Teva Pharmaceutical Industries Ltd

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference18 articles.

1. Autologous stem cell mobilization and collection;Hsu;Hematol Oncol Clin North Am,2016

2. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF;Schmitt;Vox Sang,2016

4. The economics of biosimilars;Blackstone;Am Health Drug Benefits,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial;Nature Medicine;2023-04

2. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation;Transfusion Medicine and Hemotherapy;2023

3. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials;Stem Cell Research & Therapy;2022-03-22

4. Comparison of CD34 + cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study;Transfusion;2021-09-09

5. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption;Current Oncology;2021-04-22